GOG249合格人群的实验性治疗脱研究使用:真实世界数据分析
本研究利用美国国家癌症数据库分析2004至2015年间符合GOG249入组标准的高中危及高危早期子宫内膜癌患者,发现75.8%接受全盆腔放疗,24.2%接受阴道近距离放疗联合化疗,后者使用率随时间显著增加,倾向性评分匹配后与总生存改善相关(HR 0.74,95%CI 0.58-0.93),但按FIGO分期分层后仅IB期获益。
要点
- 2004至2015年间符合GOG249标准的早期子宫内膜癌患者中,阴道近距离放疗联合化疗使用率显著增加。
- 倾向性评分匹配后,阴道近距离放疗联合化疗与总生存改善相关(HR 0.74,95%CI 0.58-0.93)。
- 按FIGO分期分层,仅IB期患者显示总生存获益(HR 0.62,95%CI 0.44-0.87)。
核心结论
- 在美国,GOG249结果报告之前,实验组脱研究治疗的使用已较为普遍。
- 鉴于疗效和毒性的不确定性,提供实验性方案脱研究治疗时应谨慎。
研究设计与样本
- 回顾性队列研究,利用美国国家癌症数据库识别2004至2015年间诊断为FIGO IA-IIB期子宫内膜样、浆液性或透明细胞子宫癌并接受子宫切除术和放疗的女性。
- 共9956名女性符合纳入标准,其中7548名(75.8%)接受全盆腔放疗,2408名(24.2%)接受阴道近距离放疗联合化疗。
- 采用Cochrane-Armitrage趋势检验评估随时间的变化趋势,单因素和多因素Cox分析计算接受阴道近距离放疗联合化疗的比值比和总生存的风险比,并进行倾向性评分匹配分析。
主要发现
- 2004至2015年间,阴道近距离放疗联合化疗的使用显著增加(p < 0.001),最大总体增幅出现在2009年,达到22%。
- 与接受阴道近距离放疗联合化疗显著相关的因素包括较高社会经济地位(p < 0.001)、较高分级子宫内膜样癌(p < 0.001)和侵袭性组织学类型(p < 0.001)。
- 倾向性评分匹配后,阴道近距离放疗联合化疗与总生存改善相关(HR 0.74,95%CI 0.58-0.93)。
- 按FIGO分期分层后,阴道近距离放疗联合化疗仅与FIGO IB期总生存改善相关(HR 0.62,95%CI 0.44-0.87)。
关键数值与推荐
- 接受全盆腔放疗者7548名(75.8%),接受阴道近距离放疗联合化疗者2408名(24.2%)。
- 倾向性评分匹配后总生存HR 0.74(95%CI 0.58-0.93)。
- FIGO IB期总生存HR 0.62(95%CI 0.44-0.87)。
临床怎么用
- 原文结论指出,提供实验性方案脱研究治疗时应谨慎,因疗效和毒性存在不确定性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Adjuvant management of women with high-intermediate- and high-risk early-stage endometrial cancer remains controversial. Recently published results of GOG 249 revealed that vaginal brachytherapy plus chemotherapy (VBT + CT) was not superior to whole pelvic radiation therapy (WPRT) and was associated with more toxicities and higher nodal recurrences. This study examined off-study utilization of VBT + CT among women who met criteria for GOG 249 in the period prior to study publication. METHODS: Women diagnosed with FIGO IA-IIB endometrioid, serous, or clear cell uterine cancer between 2004-2015 and treated with hysterectomy and radiotherapy (RT) were identified in the National Cancer Database. Cochrane-Armitrage trend test was used to assess trends over time. Univariate and multivariate Cox analyses were performed to calculate odds ratio (OR) of VBT + CT receipt and hazard ratio (HR) of OS. Propensity-score matched analysis was conducted to account for baseline differences. RESULTS: 9956 women met inclusion criteria. 7548 women (75.8%) received WPRT while 2408 (24.2%) received VBT + CT in the study period. From 2004-2015, there was a significant increase in VBT + CT use (p < 0.001) with the largest overall increase occurring in 2009 to 22%. Factors significantly associated with VBT + CT receipt included higher socioeconomic status (p < 0.001), higher grade endometrioid cancer (p < 0.001), and aggressive histology (p < 0.001). After propensity-score matching, VBT + CT was associated with improved OS (HR 0.74, 95% CI 0.58-0.93); however, when stratified by FIGO stage, VBT + CT was only associated with improved OS for FIGO stage 1B (HR 0.62, 95% CI 0.44-0.87). CONCLUSIONS: There was significant use of experimental arm off-study treatment in the United States prior to report of GOG 249 results. Providers should be cautious when offering off-study treatment utilizing an experimental regimen given uncertainty about efficacy and toxicity.
引用
- Chodavadia PA, Jacobs CD, Wang F, et al. Off-study utilization of experimental therapies: Analysis of GOG249-eligible cohorts using real world data. Gynecol Oncol. 2019. PMID: 31759772. doi:10.1016/j.ygyno.2019.09.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。